January 27, 2020 09:00 ET| Source: CytoDyn Inc.

The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV)

Based on these strong results, CytoDyn has partnered with the Thai Red Cross AIDS Research Centre (TRCARC) to conduct clinical trials evaluating the potential of leronlimab to prevent HIV; trial could begin this year

VANCOUVER, Washington, Jan. 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the acceptance of an abstract detailing the advantages of the CCR5 antibody, leronlimab, to prevent macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) at the Keystone Symposia on HIV Pathogenesis and Cure in Keystone, Colorado from March 22-26, 2020.